Trials / Completed
CompletedNCT05412303
Vaso-inotropic Score and ECMO-VA Support in Post-cardiotomy Cardiogenic Shock.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,769 (actual)
- Sponsor
- Centre Hospitalier Universitaire Dijon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a well-established lifesaving treatment for refractory cardiogenic shock, with or without concomitant respiratory failure. VA-ECMO is usually started in presence of refractory low cardiac output syndrome following CPB weaning. Currently, there is no consensus about the best timing for implantation and initiation of VA-ECMO in this setting. Some publications have suggested that VIS score could be used to determine the necessity of VA-ECMO in cardiologic area. It was demonstrated that a VIS score between 20 and 40 may be a cut-off value to discuss the implantation of VA-ECMO. Post cardiotomy shock is a very interesting setting because the timing of cardiogenic shock is known and several bias are more controlled than in medical area. Based on the well-established ability of VIS Score in predicting mortality, we will investigate the role of the VIS Score as a determinant for early VA-ECMO implantation in patients suffering of post-cardiotomy cardiogenic shock.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | data collection | age, gender, body weight, height, personal medical history, ASA score, EuroSCORE2, type of cardiac surgery, the preoperative left ventricular ejection fraction, the duration of CPB, the duration of aortic clamping, the need for intraoperative blood transfusion, norepinephrine, dobutamine, creatinine value, time to extubation (hours), any occurrence of complications during the stay in the ICU or in the hospital, and the LOS in the ICU and hospital |
Timeline
- Start date
- 2019-01-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2022-06-09
- Last updated
- 2022-06-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05412303. Inclusion in this directory is not an endorsement.